Eli Lilly issued an open letter Thursday.
Drugmaker Eli Lilly is taking a stand against the use of two of its popular medications – Mounjaro and Zepbound – for “cosmetic weight loss.”released Thursday, the company said, in part, “Mounjaro and Zepbound are indicated for the treatment of serious diseases; they are not approved for – and should not be used for – cosmetic weight loss.”
“People are using these drugs because they've just wanted lose an extra 10 to 15 pounds,” Dr. Veronica Johnson, an obesity medicine specialist at Northwestern Medicine, told “Good Morning America.” “People who don't meet the FDA-approved criteria for these medications may be putting themselves at harm because their medications have not been tested in people who have a normal BMI and don't have any other weight-related conditions.
Lilly said Mounjaro is meant to be used to improve glycemic control in adults with type 2 diabetes mellitus, while Zepbound should be used by adults with obesity or people who are overweight and have at least one additional weight-related condition, such as cardiovascular disease, high cholesterol, hypertension, or type 2 diabetes. The company also said both drugs need to be used in combination with a healthy diet and exercise.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly warns about dangers of fake and counterfeit Mounjaro, ZepboundEli Lilly also filed lawsuits against compounding pharmacies and medical spas.
Read more »
Eli Lilly warns about dangers of fake and counterfeit Mounjaro, ZepboundEli Lilly also filed lawsuits against compounding pharmacies and medical spas.
Read more »
How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat AshkenaziAshkenazi has been key to managing the windfall in revenue and wave of investor optimism from Eli Lilly's diabetes injection Mounjaro and obesity drug Zepbound.
Read more »
Eli Lilly's Alzheimer's drug donanemab advances as America's population agesAn advisory committee endorsing the drug says it's safe and effective. If approved by the FDA, donanemab would be the second drug on the market to slow the progression of the disease.
Read more »
A successful Alzheimer's drug will help Eli Lilly join the $1 trillion clubFor Eli Lilly to become the first drugmaker to soon reach that milestone market cap, it will need drugs beyond GLP-1s.
Read more »
Stocks making the biggest moves premarket: Eli Lilly, General Motors, ShopifyThese are the stocks posting the largest moves in premarket trading.
Read more »